SEC filings and other documents

Q2 sales up 12.5% with raised 2026 guidance, driven by strong TAVR and TMTT growth.

Broad-based growth, innovation, and new leadership drive sustained double-digit outlook.

Q1 2026 delivered 12.7% sales growth and raised guidance, led by strong TAVR and TMTT results.

Strong clinical data and innovation drive growth outlook, with margin expansion and new therapies ahead.

Double-digit growth targeted through innovation in TAVR, TMTT, and heart failure therapies.

TAVR and TMDT growth driven by innovation, clinical data, and expanding patient access.

TAVR acceleration, innovation, and regulatory changes drive confident growth outlook for 2026.

Next-gen heart therapies and regulatory catalysts position for double-digit growth through 2030.

Double-digit sales growth in 2025, with strong TAVR/TMTT results and robust 2026 outlook.

Poised for 8%-10% growth in 2025, with TAVR, TMTT, and surgical driving long-term acceleration.

Double-digit Q3 growth and raised guidance reflect strong TAVR, TMTT, and surgical momentum.

Long-term data confirm TAVR's durability and new devices expand treatment options for valve disease.

Double-digit Q2 growth and raised guidance reflect strong global performance and innovation.

Early TAVR approval, TMTT growth, and strategic acquisitions set the stage for multi-year expansion.

Q1 sales up 8% to $1.41B; guidance reaffirmed; TMTT outlook raised on strong growth.

Zoom is evolving into a unified work platform with AI-driven growth and disciplined financial strategy.